Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies

Marelli, Laura; Stigliano, Rosa; Triantos, Christos; Senzolo, Marco; Cholongitas, Εvangelos; Davies, Neil; Yu, Dominic; Meyer, Tim; Patch, David; Burroughs, Andrew K.

doi:10.1016/j.ctrv.2006.08.002

Cited by 78 publications

(54 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic chemotherapy, contrary to what is observed in some other digestive cancers, did not decrease this risk (16)(17)(18). Early recurrences due to the removed cancer could be prevented by treatments delivered in the hepatic artery (19); in this setting, chemoembolization seems of interest (20).…”

Section: Discussionmentioning

confidence: 87%

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Boucher

Bouguen²,

Garin³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

Recurrences after resection of hepatocellular carcinoma are frequent. A single postoperative injection of 131 I-labeled lipiodol in the hepatic artery was shown in 1999 by Lau and colleagues to be an effective adjuvant treatment, and those results were strengthened by our experience with a case-control study, reported in 2003. The goal of this paper is to update the 2003 results for a minimal follow-up of 5 y. Methods: Between January 1999 and September 2001, 38 patients were given an adjuvant postoperative intraarterial injection of 131 I-lipiodol and were matched (for Okuda group and tumor size) with 38 patients who had undergone resection between January 1997 and January 1999 without postoperative treatment. The 2 groups were similar. Results: There were 28 recurrences in the control group and 22 in the 131 I-lipiodol group (not statistically significant), and the mean time of recurrence was 21 and 26.5 mo, respectively, after surgery (statistically significant). The number of recurrences was lower in the first 2 y in the 131 I-lipiodol group (statistically significant). Disease-free survival was better (P , 0.03) in the 131 I-lipiodol group than in the control group (2-, 3-, and 5-y rates [695% confidence interval] of 77% 6 7%, 63% 6 8%, and 42% 6 8.5%, respectively, for the 131 I-lipiodol group vs. 47% 6 8%, 34% 6 8%, and 27% 6 8%, respectively, for the control group). Overall survival did not differ between the 2 groups (P 5 0.09), even though there was a trend toward better survival in the 131 I-lipiodol group (2-, 3-, and 5-y rates of 76% 6 7%, 68% 6 7.5%, and 51% 6 9%, respectively, vs. 68% 6 7.5%, 53% 6 8%, and 39% 6 8%, respectively, in the control group). Conclusion: With a longer follow-up, the results of this retrospective case-control study still favor a single postoperative injection of 131 I-lipiodol. These retrospective findings point out the need for a large-scale, prospective, randomized study. Therecurrence rate after potentially curative treatments in patients with hepatocellular carcinoma (HCC) is about 40%-60% at 2 y and 80% at 5 y (1-5). Intrahepatic recurrence can represent either de novo tumor formation in a cirrhotic liver or intrahepatic metastasis of a clonally identical neoplasm. HCC is well suited to treatment with locoregional therapy, because the disease tends to stay within the liver until advanced. The treatment of choice in this setting is local. Among the few positive randomized, controlled trials in HCC therapy (6-8), a small study demonstrated the efficacy of a single postoperative intraarterial injection of 131 I-labeled lipiodol (7). This treatment (1,850 MBq of 131 I-lipiodol) decreased the recurrence rate and improved overall and recurrence-free survival. After the publication of that series, we decided in 1999 to propose this treatment for patients undergoing complete surgical resection for HCC. In 2003, we reported our results in a casecontrol study comparing the outcome in 2 populations treated surgically, matched for tumor size and Okuda class, and differing only b...

show abstract

Section: Discussionmentioning

confidence: 87%

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Boucher

Bouguen²,

Garin³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Additionally, because the onset of liver cancer is hidden, most patients are already at the end-stage once a definite diagnosis is made (5,6), depriving them of the chance for radical treatment. Currently, the main clinical approaches to treating primary liver cancer include partial hepatectomy, systemic or local chemotherapy, radiotherapy, radiofrequency ablative surgery and liver transplantation (7)(8)(9)(10)(11). However, all of these approaches have shortcomings, including poor prognosis and many side-effects.…”

Section: Introductionmentioning

confidence: 99%

Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway

Huang

Tang

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

Abstract. Liver cancer is a malignant tumour with high morbidity and fatality rates that is common worldwide. At present, the clinical approaches to treating primary liver cancer include partial hepatectomy, systemic or local chemotherapy, radiotherapy, radiofrequency ablative surgery and liver transplantation. However, all of these approaches have shortcomings, including poor prognosis and numerous side-effects. A large number of studies have proven that many effective ingredients in traditional Chinese medicine, particularly the flavonoid compounds extracted from plants, have achieved breakthroughs in terms of enhancing the effects and reducing the toxicity of chemotherapy and radiotherapy, preventing tumour metastasis and relapse after surgery, alleviating the clinical symptoms of advanced tumours, improving the quality of life of the patient with tumours and extending patient long-term survival. The purpose of the present study was to investigate the impact of isoquercitrin, the flavonoid from Bidens bipinnata L. extract, on the progression of liver cancer and to achieve a deeper understanding of the biological characteristics of isoquercitrin's involvement in the progression of liver cancer. In the in vitro experiments, isoquercitrin was found to strongly inhibit the proliferation of human liver cancer cells, promote the apoptosis of human liver cancer cells, and block the cell cycle in the G1 phase. Isoquercitrin activated caspase-3, -8 and -9, inhibited the expression level of ERK and p38MAPK protein phosphorylation, and promoted the phosphorylation of JNK. Additionally, isoquercitrin reduced the expression level of PKC in human liver cancer cells. In the in vivo experiments, isoquercitrin was also found to significantly inhibit the growth of transplanted tumours in nude mice. The present study confirmed that isoquercitrin could inhibit the progression of human liver cancer in vivo and in vitro, and the molecular mechanism of isoquercitrin may be closely associated with the MAPK and PKC signalling pathways.

show abstract

“…TACE has been established as the standard therapy for patients with intermediate stage cancer (12), although the efficacy of TACE is limited and patients often suffer from recurrence (13). The most frequently used chemotherapeutics for TACE are doxorubicin (Adriamycin RDF), cisplatin (Platinol), and epirubicin (Ellence), either alone or in combination (14), from which doxorubicin and cisplatin showed significant benefits (13). Moreover, targeted therapeutic agents such as the multikinase inhibitor sorafenib (Nexavar) have been shown to have survival benefits especially in patients with advanced stage HCC (15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Zijl

Mall

Machat

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The epithelial to mesenchymal transition (EMT) of malignant hepatocytes is a crucial event in hepatocellular carcinoma (HCC) progression and recurrence. We aimed to establish a human model of EMT to examine drug efficacy and specificity in HCC progression. Human HCC cell populations were characterized by immunofluorescence analysis, migration and invasion assays, array comparative genomic hybridization, whole-genome expression profiling, and promoter methylation. Therapeutic agents clinically used against HCC were examined for efficacy by determination of IC 50 values. We show that liver cancer cell lines exhibited either an epithelial or mesenchymal phenotype of which the latter showed strong migratory and invasive abilities in vitro. The common cellular origin of both cell types indicated that mesenchymal HCC cells have been derived from epithelial hepatocytes through EMT in the HCC patient. Drug exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic agents sorafenib and erlotinib as compared to epithelial HCC cells, which were slightly more resistant to cytostatic drugs. Most remarkably, combined treatment with doxorubicin and sorafenib caused increased susceptibility of both HCC cell types resulting in enhanced drug efficacy. Taken together, this EMT model of human HCC allows the identification of molecular mechanisms and the assessment of therapeutic drug efficacy during liver cancer progression in preclinical studies. Mol Cancer Ther; 10(5); 850-60. Ó2011 AACR.

show abstract

Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies

Cited by 78 publications

References 53 publications

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Contact Info

Product

Resources

About

Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies

Cited by 78 publications

References 53 publications

Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Contact Info

Product

Resources

About

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up

Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up